152 related articles for article (PubMed ID: 35544035)
1. Complete Response of a Patient With a Mismatch Repair Deficient Aggressive Pituitary Adenoma to Immune Checkpoint Inhibitor Therapy: A Case Report.
Shah S; Manzoor S; Rothman Y; Hagen M; Pater L; Golnik K; Mahammedi A; Lin AL; Bhabhra R; Forbes JA; Sengupta S
Neurosurgery; 2022 Aug; 91(2):e51-e56. PubMed ID: 35544035
[TBL] [Abstract][Full Text] [Related]
2. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.
Dai C; Liang S; Sun B; Kang J
Front Endocrinol (Lausanne); 2020; 11():608422. PubMed ID: 33362722
[TBL] [Abstract][Full Text] [Related]
3. Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature.
Lizzul L; Lombardi G; Barbot M; Ceccato F; Gardiman MP; Regazzo D; Bellu L; Mazza E; Losa M; Scaroni C
Pituitary; 2020 Aug; 23(4):359-366. PubMed ID: 32232709
[TBL] [Abstract][Full Text] [Related]
4. Temozolomide retreatment in a recurrent prolactin-secreting pituitary adenoma: Hormonal and radiographic response.
Strowd RE; Salvatori R; Laterra JJ
J Oncol Pharm Pract; 2016 Jun; 22(3):517-22. PubMed ID: 25616657
[TBL] [Abstract][Full Text] [Related]
5. Early Initiation of Temozolomide Therapy May Improve Response in Aggressive Pituitary Adenomas.
Das L; Gupta N; Dutta P; Walia R; Vaiphei K; Rai A; Radotra BD; Gupta K; Sreedharanunni S; Ahuja CK; Bhansali A; Tripathi M; Sood R; Dhandapani S
Front Endocrinol (Lausanne); 2021; 12():774686. PubMed ID: 34975752
[TBL] [Abstract][Full Text] [Related]
6. DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors.
Hirohata T; Asano K; Ogawa Y; Takano S; Amano K; Isozaki O; Iwai Y; Sakata K; Fukuhara N; Nishioka H; Yamada S; Fujio S; Arita K; Takano K; Tominaga A; Hizuka N; Ikeda H; Osamura RY; Tahara S; Ishii Y; Kawamata T; Shimatsu A; Teramoto A; Matsuno A
J Clin Endocrinol Metab; 2013 Mar; 98(3):1130-6. PubMed ID: 23365123
[TBL] [Abstract][Full Text] [Related]
7. The role of temozolomide in the treatment of aggressive pituitary tumors.
Liu JK; Patel J; Eloy JA
J Clin Neurosci; 2015 Jun; 22(6):923-9. PubMed ID: 25772801
[TBL] [Abstract][Full Text] [Related]
8. Use of temozolomide in aggressive pituitary tumors: case report.
Mohammed S; Kovacs K; Mason W; Smyth H; Cusimano MD
Neurosurgery; 2009 Apr; 64(4):E773-4; discussion E774. PubMed ID: 19349807
[TBL] [Abstract][Full Text] [Related]
9. Early postoperative MRI and detection of residual adenoma after transsphenoidal pituitary surgery.
Alhilali LM; Little AS; Yuen KCJ; Lee J; Ho TK; Fakhran S; White WL
J Neurosurg; 2020 Feb; 134(3):761-770. PubMed ID: 32032952
[TBL] [Abstract][Full Text] [Related]
10. Ten years' experience with intraoperative MRI-assisted transsphenoidal pituitary surgery.
Hlaváč M; Knoll A; Mayer B; Braun M; Karpel-Massler G; Etzrodt-Walter G; Coburger J; Wirtz CR; Paľa A
Neurosurg Focus; 2020 Jun; 48(6):E14. PubMed ID: 32480376
[TBL] [Abstract][Full Text] [Related]
11. Surgery, Octreotide, Temozolomide, Bevacizumab, Radiotherapy, and Pegvisomant Treatment of an AIP Mutation‒Positive Child.
Dutta P; Reddy KS; Rai A; Madugundu AK; Solanki HS; Bhansali A; Radotra BD; Kumar N; Collier D; Iacovazzo D; Gupta P; Raja R; Gowda H; Pandey A; Devgun JS; Korbonits M
J Clin Endocrinol Metab; 2019 Aug; 104(8):3539-3544. PubMed ID: 31125088
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Temozolomide Therapy in Patients With Aggressive Pituitary Adenomas and Carcinomas-A German Survey.
Elbelt U; Schlaffer SM; Buchfelder M; Knappe UJ; Vila G; Micko A; Deutschbein T; Unger N; Lammert A; Topuzoglu-Müller T; Bojunga J; Droste M; Johanssen S; Kolenda H; Ritzel K; Buslei R; Strasburger CJ; Petersenn S; Honegger J
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31746334
[TBL] [Abstract][Full Text] [Related]
13. Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature.
Annamalai AK; Dean AF; Kandasamy N; Kovacs K; Burton H; Halsall DJ; Shaw AS; Antoun NM; Cheow HK; Kirollos RW; Pickard JD; Simpson HL; Jefferies SJ; Burnet NG; Gurnell M
Pituitary; 2012 Sep; 15(3):276-87. PubMed ID: 22076588
[TBL] [Abstract][Full Text] [Related]
14. Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab.
Lin AL; Jonsson P; Tabar V; Yang TJ; Cuaron J; Beal K; Cohen M; Postow M; Rosenblum M; Shia J; DeAngelis LM; Taylor BS; Young RJ; Geer EB
J Clin Endocrinol Metab; 2018 Oct; 103(10):3925-3930. PubMed ID: 30085142
[TBL] [Abstract][Full Text] [Related]
15. [Aggressive pituitary adenoma and pituitary carcinoma].
Tóth M
Orv Hetil; 2023 Jul; 164(30):1167-1175. PubMed ID: 37516994
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review.
Ilie MD; Vasiljevic A; Jouanneau E; Raverot G
Endocr Relat Cancer; 2022 May; 29(7):415-426. PubMed ID: 35521777
[TBL] [Abstract][Full Text] [Related]
17. Rapid disease progression in patient with mismatch-repair deficiency pituitary ACTH-secreting adenoma treated with checkpoint inhibitor pembrolizumab.
Caccese M; Barbot M; Ceccato F; Padovan M; Gardiman MP; Fassan M; Denaro L; Emanuelli E; D'Avella D; Scaroni C; Zagonel V; Lombardi G
Anticancer Drugs; 2020 Feb; 31(2):199-204. PubMed ID: 31702999
[TBL] [Abstract][Full Text] [Related]
18. Pituitary atypical adenoma or carcinoma sensitive to temozolomide combined with radiation therapy: a case report of early identification and management.
Zhong C; Yin S; Zhou P; Jiang S
Turk Neurosurg; 2014; 24(6):963-6. PubMed ID: 25448217
[TBL] [Abstract][Full Text] [Related]
19. Primary sellar melanocytic tumor mimicking hemorrhagic pituitary macroadenoma: Case report and literature review.
Zhou HJ; Zhan RY; Ma YH; Cao F; Zheng XJ
Br J Neurosurg; 2015 Apr; 29(2):298-302. PubMed ID: 25613300
[TBL] [Abstract][Full Text] [Related]
20. Clinical, Laboratory, and Treatment Profiles of Silent Corticotroph Adenomas That Have Transformed to the Functional Type: A Case Series With a Literature Review.
Zheng G; Lu L; Zhu H; You H; Feng M; Liu X; Dai C; Yao Y; Wang R; Zhang H; Sun X; Lu Z
Front Endocrinol (Lausanne); 2020; 11():558593. PubMed ID: 33071973
[No Abstract] [Full Text] [Related]
[Next] [New Search]